Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 30,800 shares, a decline of 59.6% from the August 15th total of 76,200 shares. Based on an average trading volume of 139,100 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the company are short sold. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 139,100 shares, the short-interest ratio is presently 0.2 days.

Oncotelic Therapeutics Price Performance

Shares of OTLC traded up $0.00 during midday trading on Monday, hitting $0.05. 226,070 shares of the company traded hands, compared to its average volume of 106,061. The stock has a 50-day moving average of $0.05 and a 200-day moving average of $0.05. The firm has a market cap of $22.90 million, a P/E ratio of -5.23 and a beta of -0.77. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.07.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.